Avtor/Urednik		Žegura, Branka; Gužič-Salobir, Barbara; Šebeštjen, Miran; Keber, Irena
Naslov		The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women
Tip		članek
Vir		Menopause
Vol. in št.		Letnik 13, št. 4
Leto izdaje		2006
Obseg		str. 643-50
Jezik		eng
Abstrakt		Objective: Androgenic progestins such as norethisterone acetate (NETA) may influence the effect of estradiol (E2) therapy. We compared the influence of oral E2, with and without NETA, and transdermal E2 on markers of coagulation, fibrinolysis, and inflammation and on lipids and lipoproteins in healthy postmenopausal women. Design: A total of 112 healthy postmenopausal women were randomized to receive treatment with either oral E2, with or without NETA, transdermal E2, or placebo. At baseline and after 28 weeks, levels of serum lipids and lipoproteins and markers of coagulation, fibrinolysis, and inflammation were determined. Results: Of the fibrinolytic parameters, oral E2 (P< 0.05) and E2 with NETA (P< 0.01) shortened euglobulin clot lysis time. Oral E2 decreased plasminogen activator inhibitor-1 activity (P< 0.05). Oral E2 with NETA reduced plasminogen activator inhibitor-1 antigen levels (P< 0.01) and increased D-dimer antigen levels (P< 0.001). All three modes of menopausal hormone therapy reduced tissue type plasminogen activator antigen. Of the coagulation parameters, both routes of E2 therapy decreased fibrinogen levels (P = 0.002 for oral and P = 0.007 for transdermal E2), whereas E2 with NETA showed no effect. The decrease of fibrinogen was larger after oral E2 (P = 0.02). Oral E2 with NETA reduced antithrombin III (P< 0.001) and protein C (P 0.001) activity. Oral E2 (P = 0.04) and E2 with NETA (P < 0.01) increased C-reactive protein (CRP). Transdermal E2 showed no influence on CRP. The addition of NETA influenced the change in CRP, as the increase in CRP was more pronounced after E2 without NETA (P = 0.005). The levels of serum amyloid A, interleukin-6, and tumor necrosis factor-a did not change significantly after any of the modes of hormone therapy. (Abstract truncated at 2000 characters)
Deskriptorji		POSTMENOPAUSE ESTRADIOL NORETHINDRONE FIBRINOLYSIS PLASMINOGEN ACTIVATOR INHIBITOR 1 DIMERIZATION FIBRINOGEN ANTITHROMBIN III C-REACTIVE PROTEIN LIPOPROTEIN(A) TRIGLYCERIDES TUMOR NECROSIS FACTOR AMYLOID INTERLEUKIN-6 LIPOPROTEINS, HDL CHOLESTEROL LIPOPROTEINS, LDL CHOLESTEROL